CDXSMEDIUM SIGNALFINANCIAL10-K

CDXS showed meaningful revenue growth and improved operational efficiency while managing through a strategic restructuring that included asset divestitures and business segment discontinuation.

The company appears to be successfully executing a strategic refocusing strategy, with revenue growing meaningfully while simultaneously reducing losses and improving cash flow generation. However, the substantial decline in accounts receivable and increased debt levels suggest potential collection challenges or timing issues that warrant monitoring.

Comparing 2026-03-11 vs 2025-02-27View on EDGAR →
FINANCIAL ANALYSIS

CDXS demonstrated strong top-line momentum with revenue growing over 30% while meaningfully reducing net losses and substantially improving operating cash flow performance. The balance sheet shows mixed signals, with stockholders' equity declining and total debt increasing, alongside a notable reduction in accounts receivable that may indicate collection timing or customer payment patterns. Overall, the financial picture suggests a company in transition that is showing operational improvements despite some balance sheet pressures.

FINANCIAL STATEMENT CHANGES
Accounts Receivable
Balance Sheet
-68.5%
$31.9M→$10.0M

Receivables declined — improved collection efficiency or conservative revenue recognition.

Operating Cash Flow
Cash Flow
+60.8%
-$49.4M→-$19.4M

Operating cash flow surged 60.8% — exceptional cash generation, highest quality earnings signal.

Total Debt
Balance Sheet
+38.7%
$28.9M→$40.1M

Debt increased 38.7% — substantial leverage increase; assess whether deployed for growth or covering losses.

Net Income
P&L
+32.6%
-$65.3M→-$44.0M

Net income grew 32.6% — bottom-line growth signals improving overall business health.

Revenue
P&L
+32.3%
$104.8M→$138.6M

Strong top-line growth of 32.3% — accelerating demand or successful expansion into new markets.

Operating Income
P&L
+28.7%
-$58.5M→-$41.7M

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

Stockholders Equity
Balance Sheet
-24.5%
$66.9M→$50.5M

Equity decreased 24.5% — buybacks or losses reducing book value, monitor solvency ratios.

Total Liabilities
Balance Sheet
+18.5%
$82.1M→$97.3M

Liabilities increased 18.5% — monitor debt-to-equity ratio and interest coverage.

SG&A Expense
P&L
-14.6%
$55.1M→$47.1M

SG&A reduced 14.6% — improved cost efficiency or headcount reduction improving operating margins.

R&D Expense
P&L
+13.1%
$46.3M→$52.3M

R&D investment increased 13.1% — signals commitment to future product development, though near-term margin impact.

LANGUAGE CHANGES
NEW — 2026-03-11
PRIOR — 2025-02-27
ADDED
As of March 5, 2026, there were 90,869,349 shares of the registrant s Common Stock, par value $0.0001 per share, outstanding.
SUMMARY RISK FACTORS Our business is subject to numerous risks and uncertainties, including those described in Part I, Item 1A: Risk Factors in this Annual Report on Form 10-K.
You should carefully consider these risks and uncertainties when investing in our common stock.
The principal risks and uncertainties affecting our business include the following: We have a history of net losses and we may not achieve or maintain profitability.
Failure to validate performance at scale, demonstrate regulatory acceptance, or overcome other challenges with the new technologies could impede customer adoption and our revenues.
3 If we are unable to develop and commercialize new technologies and products for the pharmaceutical and life science tools markets, our business and prospects will be harmed.
We may receive limited revenue or no future value from certain of our existing license agreements.
If our biocatalysts, or the genes that code for our biocatalysts, are stolen, misappropriated or reverse engineered, others could use these biocatalysts or genes to produce competing products.
We are subject to anti-takeover provisions in our certificate of incorporation and bylaws and under Delaware law that could delay or prevent an acquisition of our company, even if the acquisition would be beneficial to our stockholders.
International trade policies, including tariffs, sanctions and trade barriers, may adversely affect our business.
REMOVED
As of February 24, 2025, there we re 82,837,311 shares of the registrant s Common Stock, par value $0.0001 per share, outstanding.
BUSINESS COMPANY OVERVIEW We are a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, and we leverage o ur proprietary CodeEvolver directed evolution technology platform to discover, develop, enhance, and commercialize novel, high-performance enzymes and other classes of proteins.
Enzymes are naturally occurring biological molecules critical to almost all biochemical reactions that sustain life.
We focus on leveraging our technology and capacity to enhance the properties and performance of enzymes to drive pivotal improvements in manufacturing of complex therapeutics across two key focus areas: our foundational, revenue-generating pharma biocatalysis business and our Enzyme-Catalyzed Oligonucleotide Synthesis ( ECO Synthesis ) manufacturing platform, which is comprised of enzymatic tools, and processes, designed to enable large-scale manufacture of RNA interference ( RNAi ) therapeutics.
In July 2023, we announced that we discontinued investment in certain development programs, primarily in our novel biotherapeutics business segment.
As part of this strategic prioritization, during 2024 we completed the divestiture and monetization of certain biotherapeutics assets as well as certain non-core life science assets, including in genomics and next generation sequencing applications.
We also use the CodeEvolver platform technology to develop enzymes for the synthesis of RNAi therapeutics through our ECO Synthesis manufacturing platform, where our enzymes are poised to deliver many of the same benefits we offer in pharma biocatalysis across purity, yield, and improved manufacturing efficiency.
For the three other routes, our data highlighted that full-length oligos of equal quality and yields were obtained whether the fragments were made with enzymes or by traditional phosphoramididte chemistry.
In addition, it allows us to provide process development, analytical method development and other manufacturing process optimization which is required before the siRNA enters clinical-stage manufacturing and testing.
In 2025, we expect to manufacture good laboratory practice ( GLP )-grade siRNA for customers in our Innovation Lab under development services contracts model, and we anticipate entering a partnership with a large-scale contract development and manufacturing organization ( CDMO ) to use our ECO platform of enzymatic tools and processes to synthesize good manufacturing practices ( GMP ) -grade siRNA drug substance for our customers.
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →